Health - Wednesday, April 1, 2026

The FDA commissioner praised staff and listed his accomplishments in a speech to workers.

The diseases were removed from a list of tests the agency conducts for state and local health departments. Experts worry that with drastic staff reductions, the testing may not resume.

AI scribes saved doctors, across five academic medical centers, about 16 minutes per eight hours of patient care, a new study found.

The FDA has often failed to share information on how it determines whether advisory committee members have financial conflicts of interest, according to a new review.

Conducting research is hard; confirming the results is, too. And artificial intelligence isn’t yet ready to help, a major new study finds.

Millions of people start work before sunrise—but their brains aren’t ready for it. A new clinical trial has found that the wake-promoting drug solriamfetol can significantly boost alertness in early-morning shift workers struggling with shift work disorder. Participants who took the drug were able to stay awake and function better throughout full shifts, with improvements in productivity, safety, and daily performance.

Eli Lilly’s obesity pill was approved by the FDA, setting it up for fierce competition against Novo Nordisk’s new Wegovy pill.

Cells aren’t as passive as scientists once thought—they actively create internal currents to move proteins quickly and efficiently. These “cellular winds” push materials to the front of the cell, enabling faster movement and repair. Discovered by chance and confirmed with advanced imaging, this system challenges decades of textbook biology. It may also reveal why some cancer cells spread so rapidly.

In this edition of STAT's AI Prognosis: How to be a 'productive' biotech AI company, with Insilico Medicine CEO Alex Zhavoronkov, and more.

A delayed FDA decision for Orca Bio, new questions about pharma-telehealth tie-ups, and more